Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug;42(8):683-688.
doi: 10.1002/cac2.12340. Epub 2022 Jul 22.

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy

Fabio Turco  1 , Marcello Tucci  2 , Marco Donatello Delcuratolo  1 , Rosario Francesco Di Stefano  1 , Chiara Pisano  1 , Alessandro Audisio  1 , Marco Audisio  1 , Antonio Ungaro  1 , Cinzia Ortega  3 , Massimo Di Maio  4 , Giorgio Vittorio Scagliotti  1 , Consuelo Buttigliero  1
Affiliations
Editorial

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy

Fabio Turco et al. Cancer Commun (Lond). 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Figures

FIGURE 1
FIGURE 1
Proposal for a therapeutic algorithm in metastatic prostate cancer. (A) scenario 1: ADT in the hormone‐sensitive phase; (B) scenario 2: ADT + docetaxelin the hormone‐sensitive phase; (C): scenario 3: ADT + ARTA in the hormone‐sensitive phase; (D) scenario 4: ADT + ARTA + docetaxel in the hormone‐sensitive phase. *Off‐label use. #Only in symptomatic patients with exclusively bone metastases. ¶Only in patients with mutations in DNA damage repair genes. †Off‐label use only in patients with positron emission tomography‐prostate‐specific membrane antigen (PET‐PSMA)‐positive disease. Abbreviations: mPC: metastatic prostate cancer ADT: androgen deprivation therapy mHSPC: metastatic hormone‐sensitive prostate cancer mCRPC: metastatic castration‐resistant prostate cancer ARTA: androgen receptor‐targeting agent PARPi: poly(ADP‐ribose) polymerase inhibitor CABA: cabazitaxel Ra: radium 223 Lu: lutetium‐177‐PSMA‐617
See this image and copyright information in PMC

References

    1. Thomas C, Baunacke M, Erb HHH, Fussel S, Erdmann K, Putz J, et al. Systemic Triple Therapy in Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored? Cancers (Basel). 2021;14(1):8. 10.3390/cancers14010008 - DOI - PMC - PubMed
    1. Leung DK, Chiu PK, Ng CF, Teoh JY. Novel Strategies for Treating Castration‐Resistant Prostate Cancer. Biomedicines. 2021;9(4):339. 10.3390/biomedicines9040339 - DOI - PMC - PubMed
    1. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353‐66. 10.1016/S0140-6736(18)32486-3 - DOI - PMC - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone‐Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737‐46. 10.1056/NEJMoa1503747 - DOI - PMC - PubMed
    1. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134‐43. 10.6004/jnccn.2021.0008 - DOI - PubMed

Publication types